Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 18, 2012

GEN Poll Voters Divided on Prospects for Growth of Emerging Bioclusters

  • When asked how much they foresee emerging bioclusters growing in 2012, voters were somewhat evenly split but mostly optimistic. By a bare plurality (33.3%), respondents predicted that nine emerging regions identified in a recent survey by a commercial real estate firm would grow “a great deal” this year, while almost as many (30.4%) thought the emerging bioclusters would grow “somewhat.” The latter group was outnumbered, however, by the 32.4% of respondents who said they foresaw “not much” growth for the up-and-coming regions, identified by Jones Lang LaSalle as Minneapolis, Raleigh-Durham, Seattle, Chicago, Denver, Houston, Florida, Atlanta, and Indianapolis.

    While the first three are pretty established, a stronger case can be made for the rest as emerging clusters. As active as all have been, however, they remain overshadowed by the San Francisco Bay Area as well as Boston and Cambridge, MA, as the weak economy of the past four years combined with cutbacks due to mergers and acquisitions have helped consolidate U.S. biopharma activity further within the nation’s largest life science clusters. The remaining 3.9% of respondents were undecided.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »